Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry.

Importance People who smoked cigarettes may experience respiratory symptoms without spirometric airflow obstruction. These individuals are typically excluded from chronic obstructive pulmonary disease (COPD) trials and lack evidence-based therapies. Objective To define the natural history of persons with tobacco exposure and preserved spirometry (TEPS) and symptoms (symptomatic TEPS). Design, Setting, and Participants SPIROMICS II was an extension of SPIROMICS I, a multicenter study of persons aged 40 to 80 years who smoked cigarettes (>20 pack-years) with or without COPD and controls without tobacco exposure or airflow obstruction. Participants were enrolled in SPIROMICS I and II from November 10, 2010, through July 31, 2015, and followed up through July 31, 2021. Exposures Participants in SPIROMICS I underwent spirometry, 6-minute walk distance testing, assessment of respiratory symptoms, and computed tomography of the chest at yearly visits for 3 to 4 years. Participants in SPIROMICS II had 1 additional in-person visit 5 to 7 years after enrollment in SPIROMICS I. Respiratory symptoms were assessed with the COPD Assessment Test (range, 0 to 40; higher scores indicate more severe symptoms). Participants with symptomatic TEPS had normal spirometry (postbronchodilator ratio of forced expiratory volume in the first second [FEV1] to forced vital capacity >0.70) and COPD Assessment Test scores of 10 or greater. Participants with asymptomatic TEPS had normal spirometry and COPD Assessment Test scores of less than 10. Patient-reported respiratory symptoms and exacerbations were assessed every 4 months via phone calls. Main Outcomes and Measures The primary outcome was assessment for accelerated decline in lung function (FEV1) in participants with symptomatic TEPS vs asymptomatic TEPS. Secondary outcomes included development of COPD defined by spirometry, respiratory symptoms, rates of respiratory exacerbations, and progression of computed tomographic-defined airway wall thickening or emphysema. Results Of 1397 study participants, 226 had symptomatic TEPS (mean age, 60.1 [SD, 9.8] years; 134 were women [59%]) and 269 had asymptomatic TEPS (mean age, 63.1 [SD, 9.1] years; 134 were women [50%]). At a median follow-up of 5.76 years, the decline in FEV1 was -31.3 mL/y for participants with symptomatic TEPS vs -38.8 mL/y for those with asymptomatic TEPS (between-group difference, -7.5 mL/y [95% CI, -16.6 to 1.6 mL/y]). The cumulative incidence of COPD was 33.0% among participants with symptomatic TEPS vs 31.6% among those with asymptomatic TEPS (hazard ratio, 1.05 [95% CI, 0.76 to 1.46]). Participants with symptomatic TEPS had significantly more respiratory exacerbations than those with asymptomatic TEPS (0.23 vs 0.08 exacerbations per person-year, respectively; rate ratio, 2.38 [95% CI, 1.71 to 3.31], P < .001). Conclusions and Relevance Participants with symptomatic TEPS did not have accelerated rates of decline in FEV1 or increased incidence of COPD vs those with asymptomatic TEPS, but participants with symptomatic TEPS did experience significantly more respiratory exacerbations over a median follow-up of 5.8 years.

[1]  Meilan K. Han,et al.  Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. , 2022, The New England journal of medicine.

[2]  Ahmed Jamal,et al.  Tobacco Product Use Among Adults — United States, 2020 , 2022, MMWR. Morbidity and mortality weekly report.

[3]  A. Jemal,et al.  Association between disparities in intergenerational economic mobility and cause-specific mortality among Black and White persons in the United States. , 2021, Cancer epidemiology.

[4]  D. Harris,et al.  Health Disparities in Environmental and Occupational Lung Disease. , 2020, Clinics in chest medicine.

[5]  Meilan K. Han,et al.  Contribution of Individual and Neighborhood Factors to Racial Disparities in Respiratory Outcomes. , 2020, American journal of respiratory and critical care medicine.

[6]  Benjamin M. Smith,et al.  Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. , 2020, JAMA.

[7]  Benjamin M. Smith,et al.  Association of Nonobstructive Chronic Bronchitis With Respiratory Health Outcomes in Adults. , 2020, JAMA internal medicine.

[8]  Kevin McCarthy,et al.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.

[9]  David Couper,et al.  Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. , 2019, JAMA.

[10]  J. Curtis,et al.  Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS , 2019, Chest.

[11]  Raúl San José Estépar,et al.  Respiratory Symptoms in Young Adults and Future Lung Disease. The CARDIA Lung Study , 2018, American journal of respiratory and critical care medicine.

[12]  W. Bailey,et al.  Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years , 2018, Thorax.

[13]  Meilan K. Han,et al.  Variability in objective and subjective measures affects baseline values in studies of patients with COPD , 2017, PloS one.

[14]  F. Herth,et al.  The Modern Art of Reading Computed Tomography Images of the Lungs: Quantitative CT , 2017, Respiration.

[15]  E. Hoffman,et al.  Airway Mucin Concentration as a Marker of Chronic Bronchitis , 2017, The New England journal of medicine.

[16]  Meilan K. Han,et al.  Frequency of Exacerbations in COPD: An Analysis of the SPIROMICS Cohort , 2017, The Lancet. Respiratory medicine.

[17]  Richard W. Bohannon,et al.  Minimal clinically important difference for change in 6‐minute walk test distance of adults with pathology: a systematic review , 2017, Journal of evaluation in clinical practice.

[18]  D. Postma,et al.  Parametric response mapping on chest computed tomography associates with clinical and functional parameters in chronic obstructive pulmonary disease. , 2017, Respiratory medicine.

[19]  David Couper,et al.  SPIROMICS Protocol for Multicenter Quantitative Computed Tomography to Phenotype the Lungs. , 2016, American journal of respiratory and critical care medicine.

[20]  Robert Paine,et al.  Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. , 2016, The New England journal of medicine.

[21]  V. Kim,et al.  Comparison between an alternative and the classic definition of chronic bronchitis in COPDGene. , 2015, Annals of the American Thoracic Society.

[22]  Q. Hou,et al.  Assessment of Health Status in Patients with Newly Diagnosed Chronic Obstructive Pulmonary Disease , 2013, PloS one.

[23]  C. Nejjari,et al.  Psychometric evaluation of the COPD assessment test: data from the BREATHE study in the Middle East and North Africa region. , 2012, Respiratory medicine.

[24]  P. Jones,et al.  Creating scenarios of the impact of copd and their relationship to copd assessment test (CAT™) scores , 2011, BMC pulmonary medicine.

[25]  Asger Dirksen,et al.  Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. , 2010, American journal of respiratory and critical care medicine.

[26]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[27]  D. Jarvis,et al.  Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. , 2007, American journal of respiratory and critical care medicine.

[28]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[29]  Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. , 1965, Lancet.